Compare VSME & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | BRTX |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.4M |
| IPO Year | 2022 | 2015 |
| Metric | VSME | BRTX |
|---|---|---|
| Price | $1.07 | $2.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.7K | ★ 274.7K |
| Earning Date | 10-31-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.14 |
| 52 Week High | $5.38 | $4.10 |
| Indicator | VSME | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 63.82 |
| Support Level | $0.87 | $0.51 |
| Resistance Level | $0.94 | $4.10 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 0.00 | 65.62 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: marketing services and social commerce. The firm generates almost all of its revenue from marketing services, which reflects the company's business of marketing services to clients and social media platforms. The social commerce segment reflects the company's business of social commerce with customers. Geographically, the firm generates revenue from the HK SAR and Taiwan.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.